Although early phase studies with single-agent anti-PD-1 inhibitors showed potential for durable tumor responses, subsequent phase III trials could not establish the superiority of anti-PD-1 monotherapy over the long-held standard of anti-angiogenic TKI therapy, such as sorafenib, in the frontline setting [7]. This evidence concerns the gene PDCD1 and neoplasm.